| SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D | Frank Vinluan | 10/12/20 | Boston |
| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy | Frank Vinluan | 09/15/20 | Europe |
| Patient Death in Poseida Prostate Cancer Study Prompts Clinical Hold | Sarah de Crescenzo | 08/18/20 | San Diego |
| GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod | Sarah de Crescenzo | 08/06/20 | National |
| GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology | Frank Vinluan | 08/05/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients | Frank Vinluan | 07/30/20 | Boston |
| Vesigen Nabs $28M to Wrap “ARMMS” Around Large Molecule Drug Delivery | Frank Vinluan | 07/22/20 | Boston |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
| Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs | Sarah de Crescenzo | 07/07/20 | Boston |
| Artiva Bio Raises $78M to Broaden Access to Cancer Cell Therapies | Sarah de Crescenzo | 06/26/20 | San Diego |
| FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products | Joanne S. Eglovitch | 06/25/20 | National |
| Timing Is an Essential Element of Cell & Gene Therapy Product Development | Sarah de Crescenzo | 06/19/20 | Philadelphia |
| Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies | Frank Vinluan | 06/17/20 | San Francisco |
| Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug | Frank Vinluan | 06/05/20 | New York |
| From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq | Frank Vinluan | 05/15/20 | New York |
| Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System | Frank Vinluan | 05/14/20 | New York |
| Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies | Frank Vinluan | 05/12/20 | San Francisco |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Adicet Aims to Advance CAR-T Therapies in Reverse Merger with resTORbio | Sarah de Crescenzo | 04/29/20 | Boston |
| Synthorx’s Shawver Joins Silverback Therapeutics as New Top Exec | Sarah de Crescenzo | 04/22/20 | Seattle |
| Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies | Sarah de Crescenzo | 04/03/20 | San Diego |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID | Sarah de Crescenzo | 04/02/20 | National |
| Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies | Sarah de Crescenzo | 03/20/20 | San Francisco |
| Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders | Sarah de Crescenzo | 03/12/20 | Boston |
| Gilead Boosts Cancer Drug Pipeline With $4.9B Deal for Forty Seven | Frank Vinluan | 03/02/20 | San Francisco |
| Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer | Frank Vinluan | 02/06/20 | San Francisco |
| Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial | Sarah de Crescenzo | 02/06/20 | San Diego |
